We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current AURX market cap is 31.74M. The company's latest EPS is USD -0.0749 and P/E is -10.01.
| Year End 31 December 2023 | 2018 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 1.37M | 0 | 0 | 112k | 609k |
| Operating Income | -1.5M | -378k | -91k | -3.32M | -3.17M |
| Net Income | -1.54M | 7.71M | -886k | -3.17M | -3.17M |
| Year End 31 December 2023 | 2018 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 975k | 161k | 1.47M | 3.05M | 1.88M |
| Total Liabilities | 1.06M | 665k | 673k | 856k | 839k |
| Total Equity | -82k | -504k | 793k | 2.19M | 1.04M |
| Year End 31 December 2023 | 2018 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -874k | -54k | -120k | -3.71M | -3.17M |
| Investing | 2k | N/A | N/A | -60k | -7k |
| Financing | 815k | 195k | 1.37M | 4.46M | 2M |
| Market Cap | 31.74M |
| Price to Earnings Ratio | -10.01 |
| Price to Sales Ratio | 52.08 |
| Price to Cash Ratio | 34.09 |
| Price to Book Ratio | 30.55 |
| Dividend Yield | - |
| Shares Outstanding | 42.32M |
| Average Volume (1 week) | 3.69k |
| Average Volume (1 Month) | 7.3k |
| 52 Week Change | -64.29% |
| 52 Week High | 2.10 |
| 52 Week Low | 0.401 |
| Spread (Intraday) | 0.14 (18.67%) |
| Company Name | Nuo Therapeutics Inc (QB) |
| Address |
3500 south dupont highway dover, delaware 19901 |
| Website | https:// |
| Industry | coml physical, biologcl resh (8731) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
